Articles tagged "Heart/lung transplantation"

2021 American Transplant Congress
Inhibition of Fatty Acid Beta-Oxidation Prolongs Heart Allograft Survival
B. W. Wong, Y. Zhu, H. Dun, L. Ye
Surgery, Washington University School of Medicine, Saint Louis, MO
*Purpose: To test the therapeutic efficacy of pharmacological inhibition of fatty acid beta-oxidation (FAO) on acute heart allograft survival.*Methods: We used a heterotopic Balb/c donor…
2021 American Transplant Congress
Pilot Study for the Use of Shortened Preemptive Therapy with Glecaprevir/pibrentasvir (g/p) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney and Heart) of Hepatitis C Viremic Donors
B. Aqel¹, H. Khamash², A. Moss³, D. E. Steidley⁴, R. C. Dickson¹
¹Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ, ²Nephrology and Hypertension, Mayo Clinic, Phoenix, AZ, ³Transplant Surgery, Mayo Clinic, Phoenix, AZ, ⁴Cardiology, Mayo Clinic, Phoenix, AZ
*Purpose: This prospective study aims to assess the efficacy of preemptive therapy with eight days of a combination of direct-acting antivirals (DAAs) (Mavyret) (Pibrentasvir /Glecaprevir)…
2021 American Transplant Congress
Outcomes of Hepatitis C Nucleic Acid Testing Positive Donors in Aviremic Recipients With Delayed Direct-Acting Antiviral Initiation
M. Hudson, A. Webb, A. Logan, A. Silverman, A. Brueckner
Pharmacy, Tampa General Hospital, Tampa, FL
*Purpose: The purpose of this study was to assess the clinical impact of utilizing hepatitis C virus (HCV) nucleic acid testing (NAT)+ donors in HCV…
2021 American Transplant Congress
Life-supporting Multi-gene Cardiac Xenografts From Swine Demonstrate Survival >8 Months and Preclinical Efficacy for Human Clinical Trials
C. Goerlich¹, B. Griffith¹, A. Singh¹, T. Zhang¹, I. Tatarov¹, B. Lewis¹, F. Sentz¹, A. Hershfeld¹, P. Odonkor¹, B. Williams¹, E. Strauss¹, A. Tabatabai², A. Bhutta³, D. Ayares⁴, D. Kaczorowski¹, M. Mohiuddin¹
¹Surgery, University of Maryland School of Medicine, Baltimore, MD, ²Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, ³Pediatrics, Pediatric Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁴Revivicor, Inc., Blacksburg, VA
*Purpose: Cardiac xenotransplantation has been proposed to bridge the gap in organ shortage for those in end-stage heart failure without the opportunity to receive a…
2021 American Transplant Congress
P40 Homodimers Induce Il-15 to Promote Endogenous Donor-reactive Memory Cd8 T Cell Activation within High-risk Cardiac Allografts
H. Tsuda, A. Valujskikh, R. Fairchild
Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
*Purpose: Longer cold ischemic storage (CIS) time prior to transplant results in increased proliferation of endogenous donor-reactive memory CD8 T cells within complete MHC-mismatched cardiac…
2021 American Transplant Congress
The Role of Notch2 in Antibody-mediated Alloimmune Response
R. Benedetti Gassen¹, N. Murakami², T. J Borges¹, A. Al Jurdi¹, A. Alessandrini¹, L. V Riella¹
¹Center of Transplantation Science, Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
*Purpose: Antibody mediated rejection is the leading cause of chronic allograft rejection. Developing a novel therapeutic target to inhibit chronic rejection is an urgent need…
2021 American Transplant Congress
Early Outcome of Heart-Kidney Transplantation in the Current Heart Allocation System in the United States
S. Rao¹, A. Doyle¹, D. Brennan², S. Constantinescu³
¹University of Virginia, Charlottesville, VA, ²Johns Hopkins Medical Institute, Baltimore, MD, ³Lewis Katz School of Medicine at Temple University, Philadelphia, PA
*Purpose: In the United States, heart allograft allocation is a primary determinant for heart-kidney transplantation (HKT). We analyzed the OPTN dataset and compared the outcomes…
2021 American Transplant Congress
Nurse and Nurse Practitioner-lead Monoclonal Antibody Initiative for Solid Organ Transplant (sot) Recipients with Covid-19
W. Cochran¹, R. Avery², D. Brennan², N. Lawrence², A. Brown², S. Sullivan², B. Adams², M. McCarthy², S. Ellis², F. Naqvi², E. Kraus², N. Alachkar², S. Alasfar², F. Al Ammary², J. Horn², L. Hartman², L. Fessler², S. Purekal², Z. Siddiqui², D. Carter², J. Ficke², M. Kantsiper², L. Boyer², I. Gupta², A. Gurakar², D. Ostrander², J. Langlee², S. Shoham², K. Marr², P. Shah²
¹Johns Hopkins Comprehensive Transplant Center, Baltimore, MD, ²Johns Hopkins, Baltimore, MD
*Purpose: Monoclonal antibody (mAB) infusion (bamlanivimab or casirivimab/imdevimab) for symptomatic, non-hypoxemic, high-risk outpatients with COVID-19 infection, is an available early intervention for COVID-19+ SOT recipients.…
2021 American Transplant Congress
Acute Kidney Injury Requiring Dialysis in Heart Transplant Recipients is a Risk Factor for Graft Failure and Overall Mortality
M. A. Merzkani, H. Murad, A. Pottebaum, A. Java, A. Malone, J. Schilling, A. Itoh, R. Delos Santos, T. Alhamad
Transplant, Washington University, Saint Louis, MO
*Purpose: Acute Kidney Injury (AKI) is a frequent complication of heart transplantation. However, with recent allocation changes, we have increasingly complex patients with a higher…
2021 American Transplant Congress
Use of Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients: A Scoping Review
A. G. Anderson, M. Eubank, K. Murray
University of Missouri, Columbia, MO
*Purpose: Immune checkpoint inhibitors (ICI) are an emerging treatment for numerous advanced diseases, but their safety and efficacy in immunosuppressed transplant patients is not known.…

1
2
3
…
21
Next Page »